

# Total Hip Arthroplasty in 6690 Patients with Inflammatory Arthritis: Effect of Medical Comorbidities and Age on Early Mortality

Rüdiger J. Weiss, Göran Garellick, Johan Kärrholm, and Nils P. Hailer

**ABSTRACT. Objective.** We analyzed early mortality after total hip arthroplasty (THA) in patients with inflammatory arthritis (IA), adjusting for medical comorbidities and socioeconomic background.

**Methods.** Data on 6690 patients with IA who underwent THA during 1992–2012 were extracted from the Swedish Hip Arthroplasty Register. Data on comorbidity, measured using the Charlson Comorbidity Index (CCI), and socioeconomic data were gathered from the Swedish National Inpatient Register and Statistics Sweden. The CCI was divided into low (0), moderate (1–2), and high (> 2). Cox proportional hazards models were fitted to calculate adjusted HR of early mortality, with 95% CI.

**Results.** Twenty-five patients (0.4%) died within 0–90 days, giving a 90-day unadjusted survival rate of 99.6% (CI 99.5–99.8). Comorbidity was associated with an increased risk of death within 90 days postoperatively [high vs low CCI: adjusted HR 9.0 (CI 1.6–49.9)]. There was a trend toward lower risk of death during the period 1999–2005, although patients operated on during this period had more comorbidities than those operated on from 1992 to 1998. A large proportion of patients was re-admitted to hospital within 90 days after the index procedure (30.2%), but rarely for cardiovascular reasons.

**Conclusion.** Medical comorbidity and an age above 75 years are associated with a substantial increase in the risk of early death after THA in patients with IA. Awareness of potential risk factors may alert clinicians and thus improve perioperative care. (First Release May 1 2016; J Rheumatol 2016; 43:1320–7; doi:10.3899/jrheum.151287)

Key Indexing Terms:

EPIDEMIOLOGY

INFLAMMATORY ARTHRITIS

ORTHOPEDIC SURGERY

There is an overall trend toward a reduced incidence of orthopedic surgery in patients with inflammatory arthritis (IA)<sup>1</sup>. Nevertheless, this population constitutes a large proportion of all patients who undergo joint replacement surgery<sup>2</sup>. Patients with IA seem to have an increased risk of complications and early mortality following major joint arthroplasty

*From the Department of Molecular Medicine and Surgery, Section of Orthopedics and Sports Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm; Swedish Hip Arthroplasty Register, and Institute of Clinical Sciences, Department of Orthopedics, Sahlgrenska University Hospital, Gothenburg; Department of Orthopedics, Institute of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden.*

*R.J. Weiss, MD PhD, Department of Molecular Medicine and Surgery, Section of Orthopaedics and Sports Medicine, Karolinska Institutet, Karolinska University Hospital, and Swedish Hip Arthroplasty Register, Department of Orthopedics, Sahlgrenska University Hospital; G. Garellick, MD, PhD, Swedish Hip Arthroplasty Register, Department of Orthopedics, and Institute of Clinical Sciences, Sahlgrenska University Hospital; J. Kärrholm, MD, PhD, Swedish Hip Arthroplasty Register, Department of Orthopedics, and Institute of Clinical Sciences, Sahlgrenska University Hospital; N.P. Hailer, MD, Swedish Hip Arthroplasty Register, Department of Orthopedics, Sahlgrenska University Hospital, and Department of Orthopedics, Institute of Surgical Sciences, Uppsala University Hospital.*

*Address correspondence to Dr. R.J. Weiss, Department of Molecular Medicine and Surgery, Section of Orthopedics and Sports Medicine, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden. E-mail: rudiger.weiss@karolinska.se*

*Accepted for publication March 8, 2016.*

when compared to patients with osteoarthritis (OA)<sup>3,4,5,6</sup>. Because the population with IA has a high burden of medical comorbidities, this increased risk would be expected.

However, there is no consensus on the notion of increased early mortality in total hip arthroplasty (THA) patients with IA. Several studies report that early mortality after THA or total knee arthroplasty in patients with IA is not higher than in patients with OA<sup>3,6,7</sup>.

Most studies of mortality after hip arthroplasty in patients with IA lack information on medical comorbidities and socioeconomic background variables<sup>3,4,6,7,8,9,10,11,12</sup>. Thus, the risk of death — adjusted for medical comorbidities and other confounding factors — after one of the major orthopedic treatment modalities in patients with IA remains unclear.

Therefore, the aim of our study was to analyze early mortality after THA in patients with IA, taking medical comorbidities and socioeconomic background variables into account. Medical comorbidity was assessed using the widely established Charlson Comorbidity Index<sup>13</sup>. Moreover, we intended to study whether there was a temporal trend toward reduced mortality rates during the last 2 decades.

## MATERIALS AND METHODS

*Source of data.* In Sweden, all citizens have a personal identification number

that is used in every contact with healthcare providers. Since 1992, the Swedish Hip Arthroplasty Register (SHAR) contains individualized data based on this personal identification number. We therefore extracted data on all patients with IA who had an elective primary THA between 1992 and 2012. The SHAR has been repeatedly validated. National coverage is complete, and completeness of registration has been stable at around 96%–98%<sup>14,15</sup>. We did not include patients operated on for hip fracture, metastatic disease, or with revision joint replacement. The unique personal identification number for any Swedish resident allowed linkage between the SHAR and the registers mentioned below. This in turn allowed access to information on medical comorbidities and socioeconomic background variables for all patients.

Data on medical comorbidities were obtained from the Swedish National Inpatient Register (IPR)<sup>16</sup>. The Charlson Comorbidity Index (CCI) was computed based on data obtained from the year preceding the index procedure but excluding the in-patient period during which the index procedure was performed<sup>13,17</sup>. The CCI includes several major disease categories such as cardiovascular (CV), cerebrovascular, chronic pulmonary, liver, renal, and gastrointestinal, along with diabetes, and solid and hematological tumors. Each category is weighted as 1, 2, 3, or 6 points, and the score is the sum of these weightings. The cases were classified into 3 levels of comorbidity: low (score 0), moderate (score 1–2), and high (score > 2)<sup>18</sup>. Socioeconomic factors, including level of education and household and personal income, were extracted from Statistics Sweden. The level of education was presented in 4 groups (none or < 9 yrs, 9 years, high school, and university), and income was divided into quarters. Age at index surgery was divided into 3 groups (< 60, 60–75, and > 75 yrs). Persons who died or emigrated during followup were identified through the Total Population Register.

Our primary endpoint was early (0–90 days and 91–180 days) mortality after the date of the index surgery (THA). Secondary endpoints were overall survival and readmissions due to CV reasons within the first 90 days after the index procedure. CV disease was defined as myocardial infarction, chronic heart failure, peripheral vascular disease, and/or cerebrovascular disease<sup>19</sup>.

**Ethics.** Ethical approval was granted by the Regional Ethical Review Board in Gothenburg (approval number: 2013/360–13). All individuals registered in the SHAR had received written information about the SHAR and were given the choice not to participate in the register or associated research. Written informed consent for participation was not obtained, consistent with the Swedish Patient Data Law of 2009.

**Statistics.** Followup started on the day of surgery and ended on the day of death, emigration, or censorship at December 31, 2012, whichever came first. Continuous data were described using means, SD, and ranges. To describe estimation uncertainty, 95% CI were used.

Kaplan-Meier survival analysis was performed to calculate unadjusted cumulative survival. Cox proportional hazard regression models were fitted for each covariate at a time to calculate crude HR with CI, and covariates were subsequently included in multiple regression models to calculate adjusted HR with CI. The choice of covariates included in multiple regression models was based upon assessment of relevance and noninterference using directed acyclical graphs. We checked the assumption of proportionality of hazards graphically and by calculating scaled Schoenfeld residuals.

The material was divided into 3 time periods (1992–1998, 1999–2005, and 2006–2012) to investigate temporal trends in the demography, comorbidity, surgical technique, and mortality in the investigated cohort.

Logistic regression analysis was used to investigate the CCI in the 3 time periods described above, adjusting for age, sex, diagnosis, level of education, and income. The low CCI score was defined as the reference level and compared with the moderate and the high CCI score. OR were calculated together with 95% CI. The level of significance was set at  $p < 0.05$ . All analyses were performed using the PASW statistics package version 18 (SPSS Inc.) and R software (version 3.0.2) together with the “rms” and “Gmisc” packages.

**Characteristics of the study population.** We identified 6690 patients with IA who underwent at least 1 THA during the study period from 1992 to 2012. Among these, 2013 patients received a contralateral THA at a later timepoint. In cases with bilateral THA, the insertion of the first THA was chosen as the index procedure. The proportion of females was 72% and the mean age at surgery was 63 years (range 12–92). Implant survival was 90.6% (95% CI 81.1–100%) after 9.5 years. The majority (78%) of the patients had rheumatoid arthritis (RA) as their primary diagnosis. The remaining patients had inflammatory joint conditions related to other unspecified, noninfectious arthritic conditions (14%), psoriatic arthritis (5%), and ankylosing spondylitis (3%). Most patients had a moderate CCI at surgery (72%). About half of the patient cohort had a 9-year education (Table 1).

**Table 1.** Description of the study population. Data are n (%) unless otherwise indicated.

Characteristics	Values
Total	6690
Female	4803 (72)
Male	1887 (28)
Diagnosis	
Rheumatoid arthritis	5234 (78)
Other inflammatory arthritis	1456 (22)
Other unspecified, noninfectious arthritis	890 (14)
Psoriatic arthritis	343 (5)
Ankylosing spondylitis	223 (3)
Mean age at index surgery, yrs (range)	63 (12–92)
Mean followup, yrs (SD)	9.5 (5.6)
Year of surgery	
1992–1998	3445 (52)
1999–2005	1953 (29)
2006–2012	1292 (19)
Charlson Comorbidity Index	
Low	1650 (25)
Moderate	4804 (72)
High	236 (3)
Implant fixation	
Cemented	5590 (83)
Uncemented	476 (7)
Other <sup>a</sup>	587 (9)
Missing	37 (1)
Surgical approach	
Posterior	3931 (59)
Not posterior	2675 (40)
Missing	84 (1)
Revision after index surgery	
No	6058 (91)
Yes	632 (9)
Re-admission within 90 days after index surgery	
No	4669 (70)
Yes	2021 (30)
Level of education	
9 years	3125 (47)
High school	2351 (35)
University	1056 (16)
None	158 (2)
Income	
1st quarter	1719 (26)
2nd quarter	1700 (25)
3rd quarter	1646 (25)
4th quarter	1612 (24)
Unknown	13 (0)

<sup>a</sup>Hybrid, reversed hybrid, and resurfacing.

## RESULTS

*Temporal changes in the demography, medical comorbidity, and choice of surgical technique in patients with IA undergoing THA.* The sex distribution was stable over the 3 investigated time periods, and there were no major differences in the distribution of patients over the 3 age groups (Supplementary Table 1, available online at [jrheum.org](http://jrheum.org)). There was, however, an increase in the comorbidity burden in patients undergoing THA during 1999–2005 and 2006–2012 compared with 1992–1998. A moderate or a high degree of comorbidity was more common during the 2 later time periods when compared with the first period (Supplementary Table 2, available online at [jrheum.org](http://jrheum.org)). This observation remained true also after adjustment for age, sex, diagnosis, level of education, and income (Figure 1).

*Early postoperative mortality.* In total, 3088 deaths (46%) occurred in the study cohort during the entire followup period. Twenty-five patients (0.4%) died within 0–90 days, giving a 90-day unadjusted survival rate of 99.6% (CI 99.5–99.8). An additional 28 patients died within 91–180 days after surgery, resulting in an unadjusted 180-day survival rate of 99.2% (CI 98.9–99.4). Unadjusted survival after 10 years was 65.4% (CI 64.2–66.7) in the entire cohort.

Early unadjusted survival differed significantly between the group with a CCI level > 2 (high) and the group with level 0 (low). Unadjusted 180-day survival was 99.6% (CI 99.3–99.9) in the group with low comorbidity, whereas it was 99.2% (CI 98.9–99.4) in the group with moderate comorbidity, and 97.0% (CI 94.8–99.2) for patients with a high degree of comorbidities (Figure 2).

The HR for the risk of death in various time periods after the index procedure was calculated after adjustment for age, sex, type of inflammatory condition, comorbidity, time period, and socioeconomic status. We found that advanced age was associated with an increased risk of death within 90 days after surgery [> 75 yrs compared with < 60 yrs (adjusted HR 10.7)]. A high CCI (adjusted HR 9.0) increased the risk of death compared with patients with a low score (Table 2).

The covariates associated with an increased risk of death within the second time period, i.e., 91–180 days, were mostly the same as those described for the time period 0–90 days. An age between 60–75 years (adjusted HR 4.6) and above 75 years (adjusted HR 11.5) were both associated with an increased risk of death 91–180 days after THA compared with an age < 60 years (Table 3). A high degree of medical comorbidity according to the CCI also increased the risk of death

Table 2. HR for mortality 0 to 90 days after THA. Twenty-five patients died within that period.

	HR	Crude 95% CI	p	HR	Adjusted 95% CI	p
Age						
< 60 yrs	1	—	—	1	—	—
60–75 yrs	9.9	1.3–75.5	0.03	6.9	0.9–51.4	0.06
> 75 yrs	20.1	2.6–156.6	0.004	10.7	1.3–88.0	0.03
Sex						
Female	1	—	—	1	—	—
Male	1.2	0.6–2.8	0.7	1.3	0.6–3.2	0.5
Diagnosis						
RA	1	—	—	1	—	—
Other	1.1	0.5–2.8	0.8	1.7	0.6–5.0	0.3
Year of surgery						
1992–1998	1	—	—	1	—	—
1999–2005	0.4	0.1–1.2	0.1	0.4	0.1–1.3	0.1
2006–2012	0.6	0.2–1.9	0.4	0.8	0.2–2.4	0.6
Charlson Comorbidity Index						
Low	1	—	—	1	—	—
Moderate	2.2	0.6–7.4	0.2	3.3	0.8–13.0	0.09
High	7.0	1.4–34.7	0.02	9.0	1.6–49.9	0.01
Level of education						
9 yrs	1	—	—	1	—	—
High school	0.1	0.0–0.6	0.01	0.2	0.0–0.8	0.03
University	0.2	0.0–1.2	0.07	0.2	0.0–1.5	0.1
None	3.2	0.9–10.7	0.06	2.7	0.7–1.0	0.2
Income						
1st quarter	1	—	—	1	—	—
2nd quarter	0.8	0.3–2.2	0.6	1.0	0.3–3.0	1.0
3rd quarter	0.8	0.3–2.3	0.7	1.5	0.5–4.7	1.5
4th quarter	0.7	0.2–2.0	0.5	2.0	0.6–6.6	2.0

Adjustment for age, sex, diagnosis, year of surgery, Charlson Comorbidity Index, level of education, and personal income. THA: total hip arthroplasty; RA: rheumatoid arthritis.




Figure 1. Temporal trends in Charlson Comorbidity Index (CCI) associated with total hip arthroplasty in patients with inflammatory arthritis. Three time periods, investigated using logistic-regression analysis, where a low score is the comparison group and 1992-1998 the baseline time period (adjusted for age, sex, diagnosis, level of education, and income).

within this second time period (adjusted HR 6.7) when compared with a low CCI score (Table 3).

**Early mortality in different time periods.** Unadjusted 180-day survival was 98.9% (CI 98.6-99.3) during the first observation period, ranging from 1992 to 1998. From 1999 to 2005, unadjusted 180-day survival increased to 99.5% (CI 99.2-99.8), and it was 99.5% (CI 99.0-99.9) from 2006 to 2012. Multivariable analyses of the risk of mortality up to 90 days from the index date indicated no statistically significant differences between the 3 time periods. Between 91 and 180 days, the multivariable analyses showed a trend toward a lower risk of death during the period 1999 to 2005 compared with the preceding period (HR 0.4), but this finding was of borderline statistical significance ( $p = 0.07$ ; Table 3 and Figure 3).

**Risk factors for readmission for CV reasons within 90 days.** A large proportion of patients was readmitted to the hospital within 90 days after the index procedure ( $n = 2021$ , 30.2%). We identified 52 (0.8% of the study population) readmissions for CV reasons within 90 days. Advanced age was a risk factor for the adjusted HR for readmission for CV reasons within 90 days after the index procedure [60-75 yrs (adjusted HR 4.2) and > 75 yrs (adjusted HR 10.6) compared with < 60 yrs]. A high CCI [adjusted HR 3.4] was associated with an increased risk of readmission for CV reasons when compared with a low CCI (Supplementary Table 3, available online at [jrheum.org](http://jrheum.org)).

## DISCUSSION

**Early mortality after THA in patients with IA.** Our study indicates that the presence of medical comorbidity according to the CCI and an age above 75 years were associated with an increased early adjusted risk of death in patients with IA after THA. We also found that patients with IA who received THA in the most recent observation period from 2006 to 2012 had more severe medical comorbidities when compared with the first period, 1992 to 1998. Despite this, the early mortality was not increased during later periods.

We focused on mortality during the first 6 postoperative months because deaths within this timeframe are more likely related to the surgical procedure than deaths occurring thereafter. The relatively high mortality in our study population during the remaining followup period is noteworthy, and this high mortality in our cohort is probably due to the inflammatory condition *per se*, rather than a consequence of the THA<sup>11,20</sup>.

We found a mortality of 0.4% during the first 90 days after the index procedure, and a 180-day mortality of 0.8%. This number is slightly lower than most 90-day mortalities reported in the literature on early postoperative mortality in patients with IA receiving a THA. Ravi, *et al* reported a 90-day mortality rate of 0.8% in 1163 patients with RA after THA<sup>4</sup>. Parvizi, *et al* analyzed 1072 patients with RA after THA and found a 30-day mortality of 0.75%<sup>10</sup>. Stundner, *et al* described a 30-day mortality of 0.2% in 5400 patients with




Figure 2. Mortality up to 1 year after total hip arthroplasty in patients with inflammatory arthritis, stratified into 3 different categories of medical comorbidity (Charlson Comorbidity Index: low, moderate, and high). Unadjusted survival according to Kaplan-Meier.




Figure 3. Mortality up to 1 year after total hip arthroplasty in patients with inflammatory arthritis, stratified into 3 different time periods: 1992–1998, 1999–2005, and 2006–2012. Unadjusted survival according to Kaplan-Meier.



Table 3. HR for mortality 91 to 180 days after THA. There were 28 deaths in that period.

	HR	Crude 95% CI	p	HR	Adjusted 95% CI	p
Age						
< 60 yrs	1	—	—	1	—	—
60–75 yrs	5.0	1.1–22.0	0.03	4.6	1.0–20.5	0.05
> 75 yrs	12.2	2.7–54.3	0.001	11.5	2.5–53.6	0.002
Sex						
Female	1	—	—	1	—	—
Male	1.7	0.8–3.5	0.2	1.9	0.9–4.0	0.1
Diagnosis						
RA	1	—	—	1	—	—
Other	0.8	0.3–2.1	0.6	1.0	0.3–3.0	1.0
Year of surgery						
1992–1998	1	—	—	1	—	—
1999–2005	0.4	0.2–1.2	0.1	0.4	0.1–1.1	0.07
2006–2012	0.4	0.1–1.4	0.2	0.4	0.1–1.3	0.1
Charlson Comorbidity Index						
Low	1	—	—	1	—	—
Moderate	1.7	0.6–5.0	0.3	2.1	0.6–7.1	0.3
High	7.2	1.8–28.9	0.01	6.7	1.5–30.9	0.01
Level of education						
9 yrs	1	—	—	1	—	—
High school	0.5	0.2–1.2	0.1	0.9	0.4–2.3	0.8
University	0.5	0.1–1.7	0.3	1.0	0.3–3.8	1.0
None	0.0	0.0–7.9 <sup>261</sup>	1.0	0.0	0.0–1.2 <sup>292</sup>	1.0
Income						
1st quarter	1	—	—	1	—	—
2nd quarter	0.7	0.3–1.9	0.5	0.8	0.3–2.0	0.8
3rd quarter	0.6	0.2–1.7	0.4	0.8	0.3–2.3	0.8
4th quarter	0.5	0.2–1.6	0.3	0.8	0.3–2.7	0.8

Adjustment for age, sex, diagnosis, year of surgery, Charlson Comorbidity Index, level of education, and personal income. RA: rheumatoid arthritis.

RA<sup>6</sup>. A comparison of elective THA surgery in patients with systemic lupus erythematosus (SLE) or RA indicated that those with SLE had a higher in-hospital mortality (0.3%) than those with RA (0.1%)<sup>7</sup>.

The early mortality in our cohort of patients with IA was higher than the early mortality found in patients undergoing a THA as a result of OA<sup>15,21</sup>. However, other authors comparing early postoperative mortality after THA in patients with IA or OA find no strong evidence for increased mortality in the IA population. In a systematic review, Singh, *et al* concluded that RA was not associated with an increased 30-day and 90-day mortality after THA<sup>22</sup>. Concerning 30-day mortality, some contemporary studies do not find any difference in early postoperative mortality when comparing patients with RA to patients with OA<sup>5,6,7</sup>.

*The effect of comorbidity on early mortality.* Importantly, our study setting enabled us to identify and to adjust for medical comorbidities, and the high degree of medical comorbidities in this population is remarkable. In a systematic review, Berstock, *et al* identified 32 studies published on the topic of mortality after THA surgery over the last 10 years<sup>23</sup>. These authors reported a 90-day mortality of 0.65% in patients with OA after THA and also found a temporal trend toward

reduced mortality rates despite an increasing degree of comorbidity<sup>23</sup>. We also observed a decrease in mortality in the latest observation period of 2006–2012 despite increasingly comorbid patients, but — as in the above-cited study — this observation was not statistically significant. However, the finding of slightly lower or at least constant early mortality is reassuring for patients with IA undergoing elective THA. The reasons for this observation are certainly multifactorial, and changes in surgical technique and improved perioperative care and anesthesia management may have contributed.

The observed increase in the comorbidity burden over time in patients with IA undergoing THA surgery is paralleled by an increased comorbidity in patients undergoing THA for other reasons. Several other studies report an increase in the comorbidity burden over time in unselected patients undergoing THA<sup>24,25,26,27,28</sup>. We found that a perioperative high CCI compared with a low score increased the risk of early mortality after THA. The CCI has been shown to correlate with the risk of morbidity and mortality in surgical patients<sup>13</sup>. However, this classification system has not been validated in patients with IA undergoing THA. Singh, *et al* analyzed 90-day complications after THA in patients with unselected

operative diagnoses<sup>26</sup>. He reported that a higher American Society of Anesthesiologists (ASA) score (III–IV) was a risk factor for cardiac events. Mahomed, *et al* studied 61,568 patients after elective primary THA for reasons other than a hip fracture<sup>29</sup>. Patients with a CCI of 1 or more had a greater risk of adverse outcomes, particularly 90-day mortality. Kirksey, *et al* documented the association of a high Deyo comorbidity index with an increased in-hospital mortality in a large sample of unselected patients after THA in a US cohort<sup>28</sup>.

*Other risk factors associated with early mortality.* Unsurprisingly, we identified advanced age as a risk factor for early mortality. Apart from the obvious fact that death is more probable the older the patient, this observation may stem from the higher degree of preexisting medical comorbidities in elderly patients, and the lesser ability of elderly patients to cope with the hemodynamic strains associated with major surgery. Advanced age as a risk factor for adverse outcomes after elective THA is described by other authors<sup>29</sup>.

In our investigation, socioeconomic factors were not statistically significantly associated with the risk of early mortality, although other studies indicated that socioeconomic background exerts a profound influence on mortality over longer followup periods in Swedish cohorts<sup>30</sup>. A study of a Swedish population of patients with RA concluded that “socioeconomic class had no effect on treatment or outcome [...]”<sup>31</sup>. However, because socioeconomic background is known to have a profound influence on short-term and longterm mortality, it may be that the moderate size of our study population in combination with the relatively low early mortality leads to insufficient statistical power to detect effects of variations in socioeconomic background variables.

It has been suggested that cemented fixation of THA increases perioperative mortality when compared with uncemented THA<sup>32</sup>. This suggestion has been strongly opposed for several reasons, and among other shortcomings, the lack of adjustment for medical comorbidities and socioeconomic background variables have been pointed out as weaknesses of that study<sup>33</sup>. It would have been interesting to investigate this issue in the context of a cohort of patients with IA, but the number of events per fixation subgroup was not high enough to enable such analyses (data not shown).

*Re-admissions to hospital.* A very high proportion of our cohort (30%) was re-admitted to hospital within 90 days after the index date. Because CV morbidity and mortality are high in patients with IA, we investigated the endpoint early re-admissions to hospital for CV reasons. We found that only a minority of patients with IA were re-admitted for such reasons, and risk factors for re-admissions for CV reasons were an age of 60 years and above and a high CCI. These findings are supported by data on the re-admission after THA or total knee arthroplasty in patients older than 65 years, where age and CV disease were associated with the risk of early re-admission<sup>34</sup>. The finding of comorbidity as a

predictor of 30-day re-admission after THA was also described to be dependent on ASA grade<sup>35</sup>.

*Strengths and limitations.* Shortcomings of our study were related to its observational, registry-based design, with the typical inherent limitations concerning registration completeness, selection bias, and thus compromised validity. The proportion of higher comorbidity scores increased during the entire study period. It is reasonable to assume that this phenomenon is in part due to the introduction of reimbursements based on diagnosis-related groups<sup>24</sup>. Thus, observations of increased comorbidity burdens over time must be interpreted with caution.

There are confounders we were unable to adjust for, such as smoking habits, body mass index, and medication, which all exert an influence on our primary outcome. On the other hand, strengths of our study included the nationwide population-based design, a relatively large sample size, and adjustment for the important confounders medical comorbidity as well as socioeconomic background. Owing to the design of the Swedish registries, we had a high degree of registration completeness, and apart from persons who emigrated, near completeness of followup. The Swedish IPR was launched in 1964 but complete coverage did not begin until 1987. Currently, more than 99% of all somatic and psychiatric hospital discharge diagnoses are registered in the IPR<sup>16</sup>. Our followup period of almost 10 years was rather long and the investigated time span from 1992 to 2012 allowed for direct comparisons between different calendar periods.

We found that medical comorbidity and age above 75 years were important risk factors for early mortality after THA in patients with IA. This information is important when discussing the risks for such patients scheduled for THA, and especially in those with medical comorbidities. Awareness of such risk factors associated with increased early mortality may alert orthopedic surgeons to patients who are potentially at risk, and this awareness could thus contribute to improved perioperative care.

## ACKNOWLEDGMENT

We thank all the Swedish orthopedic surgeons and secretaries who contributed data.

## ONLINE SUPPLEMENT

Supplementary data for this article are available online at [jrheum.org](http://jrheum.org).

## REFERENCES

1. Weiss RJ, Stark A, Wick MC, Ehlin A, Palmblad K, Wretenberg P. Orthopaedic surgery of the lower limbs in 49,802 rheumatoid arthritis patients: results from the Swedish National Inpatient Registry during 1987 to 2001. *Ann Rheum Dis* 2006;65:335-41.
2. Louie GH, Ward MM. Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983-2007. *Ann Rheum Dis* 2010;69:868-71.
3. Ravi B, Escott B, Shah PS, Jenkinson R, Chahal J, Bogoch E, et al. A systematic review and meta-analysis comparing complications

- following total joint arthroplasty for rheumatoid arthritis versus for osteoarthritis. *Arthritis Rheum* 2012;64:3839-49.
4. Ravi B, Croxford R, Hollands S, Paterson JM, Bogoch E, Kreder H, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. *Arthritis Rheumatol* 2014;66:254-63.
  5. Bozic KJ, Lau E, Kurtz S, Ong K, Rubash H, Vail TP, et al. Patient-related risk factors for periprosthetic joint infection and postoperative mortality following total hip arthroplasty in Medicare patients. *J Bone Joint Surg Am* 2012;94:794-800.
  6. Stundner O, Chiu YL, Sun X, Goodman SM, Russell LA, Calloway JJ, et al. Perioperative outcomes in patients with rheumatoid versus osteoarthritis for total hip arthroplasty: a population-based study. *Clin Exp Rheumatol* 2013;31:889-95.
  7. Domsic RT, Lingala B, Krishnan E. Systemic lupus erythematosus, rheumatoid arthritis, and postarthroplasty mortality: a cross-sectional analysis from the nationwide inpatient sample. *J Rheumatol* 2010;37:1467-72.
  8. Garland A, Rolfson O, Garellick G, Kärrholm J, Hailer NP. Early postoperative mortality after simultaneous or staged bilateral primary total hip arthroplasty: an observational register study from the Swedish Hip Arthroplasty Register. *BMC Musculoskelet Disord* 2015;16:77.
  9. Michaud K, Fehringer EV, Garvin K, O'Dell JR, Mikuls TR. Rheumatoid arthritis patients are not at increased risk for 30-day cardiovascular events, infections, or mortality after total joint arthroplasty. *Arthritis Res Ther* 2013;15:R195.
  10. Parvizi J, Johnson BG, Rowland C, Ereth MH, Lewallen DG. Thirty-day mortality after elective total hip arthroplasty. *J Bone Joint Surg Am* 2001;83:1524-8.
  11. Lie SA, Engesaeter LB, Havelin LI, Gjessing HK, Vollset SE. Mortality after total hip replacement: 0-10-year follow-up of 39,543 patients in the Norwegian Arthroplasty Register. *Acta Orthop Scand* 2000;71:19-27.
  12. Soohoo NF, Farg E, Lieberman JR, Chambers L, Zingmond DS. Factors that predict short-term complication rates after total hip arthroplasty. *Clin Orthop Relat Res* 2010;468:2363-71.
  13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373-83.
  14. Soderman P, Malchau H, Herberts P, Johnell O. Are the findings in the Swedish National Total Hip Arthroplasty Register valid? A comparison between the Swedish National Total Hip Arthroplasty Register, the National Discharge Register, and the National Death Register. *J Arthroplasty* 2000;15:884-9.
  15. Swedish Hip Arthroplasty Register, Annual Report 2013. [Internet. Accessed March 11, 2016.] Available from: [www.shpr.se/en/](http://www.shpr.se/en/)
  16. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. *BMC Public Health* 2011;11:450.
  17. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. A critical review of available methods. *J Clin Epidemiol* 2003;56:221-9.
  18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol* 1992;45:613-9.
  19. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *Am J Epidemiol* 2011;173:676-82.
  20. Dadoun S, Zeboulon-Ktorza N, Combescure C, Elhai M, Rozenberg S, Gossec L, et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. *Joint Bone Spine* 2013;80:29-33.
  21. Shourt CA, Crowson CS, Gabriel SE, Matteson EL. Orthopedic surgery among patients with rheumatoid arthritis 1980-2007: a population-based study focused on surgery rates, sex, and mortality. *J Rheumatol* 2012;39:481-5.
  22. Singh JA, Kundukulam J, Riddle DL, Strand V, Tugwell P. Early postoperative mortality following joint arthroplasty: a systematic review. *J Rheumatol* 2011;38:1507-13.
  23. Berstock JR, Beswick AD, Lenguerrand E, Whitehouse MR, Blom AW. Mortality after total hip replacement surgery: a systematic review. *Bone Joint Res* 2014;3:175-82.
  24. Gordon M, Stark A, Skoldenberg OG, Kärrholm J, Garellick G. The influence of comorbidity scores on re-operations following primary total hip replacement: comparison and validation of three comorbidity measures. *Bone Joint J* 2013;95:1184-91.
  25. Cram P, Lu X, Kaboli PJ, Vaughan-Sarrazin MS, Cai X, Wolf BR, et al. Clinical characteristics and outcomes of Medicare patients undergoing total hip arthroplasty, 1991-2008. *JAMA* 2011;305:1560-7.
  26. Singh JA, Jensen MR, Harmsen WS, Gabriel SE, Lewallen DG. Cardiac and thromboembolic complications and mortality in patients undergoing total hip and total knee arthroplasty. *Ann Rheum Dis* 2011;70:2082-8.
  27. Jimenez-Garcia R, Villanueva-Martinez M, Fernandez-de-Las-Penas C, Hernandez-Barrera V, Rios-Luna A, Garrido PC, et al. Trends in primary total hip arthroplasty in Spain from 2001 to 2008: evaluating changes in demographics, comorbidity, incidence rates, length of stay, costs and mortality. *BMC Musculoskelet Disord* 2011;12:43.
  28. Kirksey M, Chiu YL, Ma Y, Della Valle AG, Poulosides L, Gerner P, et al. Trends in in-hospital major morbidity and mortality after total joint arthroplasty: United States 1998-2008. *Anesth Analg* 2012;115:321-7.
  29. Mahomed NN, Barrett JA, Katz JN, Phillips CB, Losina E, Lew RA, et al. Rates and outcomes of primary and revision total hip replacement in the United States Medicare population. *J Bone Joint Surg Am* 2003;85:27-32.
  30. Padyab M, Malmberg G, Norberg M, Blomstedt Y. Life course socioeconomic position and mortality: a population register-based study from Sweden. *Scand J Public Health* 2013;41:785-91.
  31. Andersson ML, Bergman S, Soderlin MK. The effect of socioeconomic class and immigrant status on disease activity in rheumatoid arthritis: data from BARFOT, a multi-centre study of early RA. *Open Rheumatol J* 2013;7:105-11.
  32. McMinn DJ, Snell KI, Daniel J, Treacy RB, Pynsent PB, Riley RD. Mortality and implant revision rates of hip arthroplasty in patients with osteoarthritis: registry based cohort study. *BMJ* 2012;344:e3319.
  33. Whitehouse SL, Bolland BJ, Howell JR, Crawford RW, Timperley AJ. Mortality following hip arthroplasty — inappropriate use of National Joint Registry (NJR) data. *J Arthroplasty* 2014;29:1827-34.
  34. Higuera CA, Elsharkawy K, Klika AK, Brocone M, Barsoum WK. 2010 Mid-America Orthopaedic Association Physician in Training Award: predictors of early adverse outcomes after knee and hip arthroplasty in geriatric patients. *Clin Orthop Relat Res* 2011;469:1391-400.
  35. Pugely AJ, Callaghan JJ, Martin CT, Cram P, Gao Y. Incidence of and risk factors for 30-day readmission following elective primary total joint arthroplasty: analysis from the ACS-NSQIP. *J Arthroplasty* 2013;28:1499-504.